MilliporeSigma
  • Putative transmembrane domain 6 of the human organic anion transporting polypeptide 1A2 (OATP1A2) influences transporter substrate binding, protein trafficking, and quality control.

Putative transmembrane domain 6 of the human organic anion transporting polypeptide 1A2 (OATP1A2) influences transporter substrate binding, protein trafficking, and quality control.

Molecular pharmaceutics (2014-11-12)
Ting Chan, Jian Zheng, Ling Zhu, Thomas Grewal, Michael Murray, Fanfan Zhou
ABSTRACT

The human organic anion transporting polypeptides (OATPs) are a family of important membrane proteins that mediate the cellular influx of various anionic substances including clinically important drugs. Transmembrane domain 6 (TM6) is a distinctive consensus "signature" common to all OATPs. Two naturally occurring variants were previously identified in TM6 of the important transporter OATP1A2; these variants may be associated with suboptimal drug influx into cells. Because of the potential importance of TM6 in drug efficacy, this study investigated its role in substrate uptake by OATP1A2. Single amino acid replacements were introduced into TM6 of OATP1A2 (residues 245-266) by alanine-scanning mutagenesis. Uptake assays, biotinylation and immunoblotting were used to assess the function and expression of OATP1A2 and its mutants after overexpression in HEK293 cells. Uptake of the model substrates estrone-3-sulfate and methotrexate by OATP1A2 mutants carrying amino acid replacements within the TM6 subregions of 245-248 and 261-266 was impaired, while transport function was largely retained by other mutants. From kinetic, biotinylation, and immunoblot analysis the diminished function of the 245-248 and 261-266 mutants was due primarily to decreased plasma membrane and total cell expression and also to a less extent, impacted by altered substrate binding. Further experiments with proteasomal or lysosomal inhibitors were consistent with impaired maturation and impaired plasma membrane insertion of several mutants of OATP1A2 within the subregions of 245-248 and 261-266. In addition, the finding that total cellular expression, but not plasma membrane expression, was less impaired for the W245A and W246A mutants suggests that these two TM6 residues might be involved in membrane targeting of OATP1A2. These findings implicate the TM6 subregions of 245-248 and 261-266 in substrate binding, protein trafficking, and quality control of OATP1A2.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Potassium phosphate monobasic, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Sigma-Aldrich
Potassium phosphate monobasic, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
Potassium phosphate monobasic, for molecular biology, ≥98.0%
Sigma-Aldrich
Potassium phosphate monobasic, 99.99% trace metals basis
Sigma-Aldrich
Potassium phosphate monobasic, ReagentPlus®
Sigma-Aldrich
Potassium phosphate monobasic, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
USP
Monobasic potassium phosphate, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Potassium phosphate monobasic, ACS reagent, ≥99.0%
Supelco
Monobasic Potassium Phosphate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Potassium phosphate monobasic, meets analytical specification of Ph. Eur., NF, E340, anhydrous, 98-100.5% (calc. to the dried substance)
Sigma-Aldrich
Potassium phosphate monobasic, buffer substance, anhydrous, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%
SAFC
Methotrexate
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Methotrexate, meets USP testing specifications
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard